Literature DB >> 19358621

Low-molecular-weight heparin prophylaxis of deep vein thrombosis for older patients with restricted mobility: propensity analyses of data from two multicentre, cross-sectional studies.

José Labarère1, Marie-Antoinette Sevestre, Joël Belmin, Annie Legagneux, Marie-Thérèse Barrellier, Hélène Thiel, Philippe Le Roux, Gilles Pernod, Jean-Luc Bosson.   

Abstract

BACKGROUND: Although older patients with restricted mobility are at increased risk for venous thromboembolism, they are under-represented in clinical trials evaluating prophylactic treatments against deep vein thrombosis (DVT).
OBJECTIVE: To determine whether prolonged prophylaxis with low-molecular-weight heparin (LMWH) is associated with a lower rate of DVT in older patients with restricted mobility.
METHODS: Two cross-sectional studies were conducted in 50 hospital-based, post-acute care facilities in France in 2001 and 2003. The studies included 1603 evaluable patients aged >or=65 years, including 866 LMWH users (median treatment duration 23 days; interquartile range 13-42) and 737 LMWH non-users. All patients underwent complete compression ultrasonography performed by board-certified vascular medicine physicians. The primary study outcome was proximal DVT. Propensity analyses were used to control for bias in LMWH treatment assignment.
RESULTS: The rate of proximal DVT was 4% (35/866) and 5.7% (42/737) for LMWH users and non-users, respectively (p = 0.16). Prophylaxis with LMWH was associated with decreased odds of proximal DVT after adjusting for baseline characteristics (odds ratio [OR] 0.56; 95% CI 0.33, 0.95; p = 0.03) or quintile of propensity score (OR 0.58; 95% CI 0.35, 0.99; p = 0.04). In propensity matched analysis, 342 LMWH users were at decreased odds of proximal DVT compared with 342 non-users (OR 0.50; 95% CI 0.24, 1.00; p = 0.04). The decrease in proximal DVT was paralleled by a similar decrease in distal DVT. Compared with non-users, only high-risk dose users had decreased odds of DVT.
CONCLUSIONS: In this observational study, prophylaxis with a high-risk dose of LMWH was associated with decreased odds of proximal DVT in older patients with restricted mobility. Further study is needed before recommending routine prophylaxis with LMWH in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19358621     DOI: 10.2165/00002512-200926030-00007

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  30 in total

Review 1.  Invited commentary: propensity scores.

Authors:  M M Joffe; P R Rosenbaum
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

2.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 3.  Low-molecular-weight heparins: are they all the same?

Authors:  Richard H White; Jeffrey S Ginsberg
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

Review 4.  Challenges in the prevention of venous thromboembolism in the elderly.

Authors:  G Di Minno; A Tufano
Journal:  J Thromb Haemost       Date:  2004-08       Impact factor: 5.824

5.  Brief report: graduated compression stocking thromboprophylaxis for elderly inpatients: a propensity analysis.

Authors:  Jose Labarere; Jean-Luc Bosson; Marie-Antoinette Sevestre; Anne-Sophie Delmas; Stéphane Dupas; Marie-Hélène Thenault; Annie Legagneux; Gudrun Boge; Béatrice Terriat; Gilles Pernod
Journal:  J Gen Intern Med       Date:  2006-09-25       Impact factor: 5.128

6.  Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.

Authors:  Nils Kucher; Alain Leizorovicz; Paul T Vaitkus; Alexander T Cohen; Alexander G G Turpie; Carl-Gustav Olsson; Samuel Z Goldhaber
Journal:  Arch Intern Med       Date:  2005-02-14

Review 7.  Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.

Authors:  R D Hull; G F Pineo; P D Stein; A F Mah; S M MacIsaac; O E Dahl; M Butcher; R F Brant; W A Ghali; D Bergqvist; G E Raskob
Journal:  Ann Intern Med       Date:  2001-11-20       Impact factor: 25.391

8.  Agreement of four competing guidelines on prevention of venous thromboembolism and comparison with observed physician practices: a cross-sectional study of 1,032 medical inpatients.

Authors:  José Labarère; Jean-Luc Bosson; Jean-François Bergmann; Nathalie Thilly
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

9.  Risk factors for deep vein thrombosis in older patients: a multicenter study with systematic compression ultrasonography in postacute care facilities in France.

Authors:  Elodie Sellier; Jose Labarere; Marie-Antoinette Sevestre; Joel Belmin; Helene Thiel; Pascal Couturier; Jean-Luc Bosson
Journal:  J Am Geriatr Soc       Date:  2007-12-07       Impact factor: 5.562

10.  Deep vein thrombosis in elderly patients hospitalized in subacute care facilities: a multicenter cross-sectional study of risk factors, prophylaxis, and prevalence.

Authors:  Jean-Luc Bosson; Jose Labarere; Marie Antoinette Sevestre; Joel Belmin; Laurence Beyssier; Antoine Elias; Alain Franco; Philippe Le Roux
Journal:  Arch Intern Med       Date:  2003-11-24
View more
  1 in total

1.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.